All In Biotech

Drug Trial Radar · NCT05707390

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide in Healthy Participants and Those With Mild, Moderate, and Severe Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Feb 20, 2023

Primary completion

Sep 13, 2023

Study completion Sep 13, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • MezigdomideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Up to 6 days
  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-T])Time frame: Up to 6 days
  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])Time frame: Up to 6 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • PANAX

    Miami Lakes, Florida

  • Orlando Clinical Research Center OCRC

    Orlando, Florida

  • The Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.